Aaron Wealth Advisors LLC Invests $462,000 in 10x Genomics $TXG

Aaron Wealth Advisors LLC purchased a new position in shares of 10x Genomics (NASDAQ:TXG) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 39,530 shares of the company’s stock, valued at approximately $462,000.

Other large investors also recently bought and sold shares of the company. Allworth Financial LP lifted its stake in 10x Genomics by 150.4% in the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after purchasing an additional 1,364 shares in the last quarter. True Wealth Design LLC increased its holdings in shares of 10x Genomics by 1,552.5% in the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock valued at $42,000 after purchasing an additional 3,369 shares during the last quarter. Blue Trust Inc. lifted its position in 10x Genomics by 48.1% during the second quarter. Blue Trust Inc. now owns 4,894 shares of the company’s stock worth $57,000 after buying an additional 1,590 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in 10x Genomics by 153.6% during the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company’s stock worth $45,000 after buying an additional 3,119 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in 10x Genomics by 203.9% during the second quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after buying an additional 5,025 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analysts Set New Price Targets

TXG has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their price target on 10x Genomics from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Wall Street Zen downgraded shares of 10x Genomics from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. UBS Group boosted their target price on shares of 10x Genomics from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Piper Sandler raised their price target on shares of 10x Genomics from $15.00 to $19.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. Finally, Citigroup lowered shares of 10x Genomics from a “buy” rating to a “cautious” rating in a research report on Thursday, December 11th. Four analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, 10x Genomics has a consensus rating of “Hold” and an average price target of $15.73.

10x Genomics Trading Up 1.6%

TXG opened at $16.00 on Friday. The stock’s 50-day moving average price is $15.37 and its 200 day moving average price is $13.45. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $20.34. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of -25.81 and a beta of 2.15.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.05. The company had revenue of $149.00 million during the quarter, compared to the consensus estimate of $142.50 million. 10x Genomics had a negative return on equity of 11.50% and a negative net margin of 11.89%.10x Genomics’s revenue was down 1.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.30) EPS. On average, research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.

Insider Activity at 10x Genomics

In related news, CFO Adam Taich sold 11,888 shares of 10x Genomics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $225,872.00. Following the completion of the transaction, the chief financial officer owned 297,385 shares in the company, valued at approximately $5,650,315. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Benjamin J. Hindson sold 8,283 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $157,377.00. Following the sale, the insider owned 432,605 shares in the company, valued at approximately $8,219,495. This trade represents a 1.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 33,432 shares of company stock worth $635,208. Corporate insiders own 9.39% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.